Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
Vera Therapeutics has announced positive results from their Phase 2b ORIGIN clinical trial for atacicept, a novel investigational…
RAPT Therapeutics Announces Promising Phase 2 Trial Results for Tivumecirnon
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced promising results from its Phase 2 clinical trial of Tivumecirnon…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
Biopharma MacroGenics, Inc. (NASDAQ: MGNX) announced that the final overall survival (OS) analysis did not demonstrate a statistically…
Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)
Capricor Therapeutics Announces HOPE-2 Trial Data Presentation On September 2nd, Capricor Therapeutics (NASDAQ: CAPR) announced an upcoming company…
Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory…
Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy…